TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT07052682

A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.
“Study was terminated early by the sponsor due to a strategic shift and reprioritization of clinical programs within Takeda.”

The sponsor’s own words in the registry.

Life of this trial

2023202420252026Started2023-01-18Stopped2024-12-30Registered2025-06-30Results posted2025-08-19

Vital statistics

Status
Terminated
Phase
Phase 1
Sponsor
Takeda
Sponsor type
Industry
Conditions
Steatohepatitis
Interventions
Ontamalimab
Participants
11
Sites
15
Countries
United States

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.